Neurobiological Technologies Valuation
| NTIIDelisted Stock | USD 0.0001 0.00 0.00% |
Neurobiological Technologies seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Neurobiological Technologies from analyzing the firm fundamentals such as Return On Equity of 1.0, shares outstanding of 27.02 M, and Operating Margin of 0.77 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Neurobiological Technologies' price fluctuation is very steady at this time. Calculation of the real value of Neurobiological Technologies is based on 3 months time horizon. Increasing Neurobiological Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurobiological Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurobiological Stock. However, Neurobiological Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.5E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Neurobiological Technologies' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Neurobiological Technologies' stock price.
Estimating the potential upside or downside of Neurobiological Technologies helps investors to forecast how Neurobiological stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurobiological Technologies more accurately as focusing exclusively on Neurobiological Technologies' fundamentals will not take into account other important factors: Neurobiological Technologies Total Value Analysis
Neurobiological Technologies is now forecasted to have valuation of (26.24 M) with market capitalization of 10.86 K, debt of 0, and cash on hands of 26.49 M. The negative valuation of Neurobiological Technologies may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Neurobiological Technologies fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(26.24 M) | 10.86 K | 0 | 26.49 M |
Neurobiological Technologies Investor Information
The company has price-to-book ratio of 0.07. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurobiological Technologies last dividend was issued on the 27th of December 2012. The entity had 1:7 split on the 17th of September 2007. Based on the key indicators related to Neurobiological Technologies' liquidity, profitability, solvency, and operating efficiency, Neurobiological Technologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Neurobiological Technologies Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Neurobiological signifies not a very effective usage of assets in December.Neurobiological Technologies Ownership Allocation
Neurobiological Technologies maintains a total of 27.02 Million outstanding shares. Roughly 90.59 % of Neurobiological Technologies outstanding shares are held by general public with 9.41 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neurobiological Technologies Profitability Analysis
The company reported the previous year's revenue of 6.03 M. Net Income was 4.94 M with profit before overhead, payroll, taxes, and interest of 26.35 M.About Neurobiological Technologies Valuation
An absolute valuation paradigm, as applied to Neurobiological Stock, attempts to find the value of Neurobiological Technologies based on its fundamental and basic technical indicators. By analyzing Neurobiological Technologies's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Neurobiological Technologies's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurobiological Technologies. We calculate exposure to Neurobiological Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurobiological Technologies's related companies.Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. The company was founded in 1987 and is based in Emeryville, California. Neurobiological Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |